194 related articles for article (PubMed ID: 34737243)
1. Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation.
Hwang HS; Yoo JE; Han DH; Choi JS; Lee JG; Joo DJ; Kim MS; Kim SI; Choi GH; Park YN
Gut Liver; 2022 May; 16(3):443-455. PubMed ID: 34737243
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
3. Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma.
Asakura N; Nakamura N; Muroi A; Nojima Y; Yamashita T; Kaneko S; Ikeda K; Koshikawa N; Suzuki T
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445353
[TBL] [Abstract][Full Text] [Related]
4. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.
Zeng Z; Ren J; O'Neil M; Zhao J; Bridges B; Cox J; Abdulkarim B; Schmitt TM; Kumer SC; Weinman SA
BMC Cancer; 2012 Dec; 12():584. PubMed ID: 23216644
[TBL] [Abstract][Full Text] [Related]
5. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
6. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
[TBL] [Abstract][Full Text] [Related]
7. Quantified postsurgical small cell size CTCs and EpCAM
Wang L; Li Y; Xu J; Zhang A; Wang X; Tang R; Zhang X; Yin H; Liu M; Wang DD; Lin PP; Shen L; Dong J
Cancer Lett; 2018 Jan; 412():99-107. PubMed ID: 29031565
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma.
Choi GH; Kim GI; Yoo JE; Na DC; Han DH; Roh YH; Park YN; Choi JS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1444-52. PubMed ID: 25791790
[TBL] [Abstract][Full Text] [Related]
9. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S
Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199
[TBL] [Abstract][Full Text] [Related]
11. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells.
Lai HC; Yeh CC; Jeng LB; Huang SF; Liao PY; Lei FJ; Cheng WC; Hsu CL; Cai X; Chang C; Ma WL
Oncotarget; 2016 Jul; 7(29):46448-46465. PubMed ID: 27340775
[TBL] [Abstract][Full Text] [Related]
13. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
14. Anterior Approach to Improve the Prognosis in HCC Patients Via Decreasing Dissemination of EpCAM
Hao S; Chen S; Tu C; Huang T
J Gastrointest Surg; 2017 Jul; 21(7):1112-1120. PubMed ID: 28378318
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
Kelley RK; Magbanua MJ; Butler TM; Collisson EA; Hwang J; Sidiropoulos N; Evason K; McWhirter RM; Hameed B; Wayne EM; Yao FY; Venook AP; Park JW
BMC Cancer; 2015 Mar; 15():206. PubMed ID: 25884197
[TBL] [Abstract][Full Text] [Related]
16. Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma.
Kim MK; Shin SJ; Lee HM; Choi HS; Jeong J; Kim H; Paik SS; Kim M; Choi D; Ryu CJ
Cancer Lett; 2019 Jul; 454():44-52. PubMed ID: 30980864
[TBL] [Abstract][Full Text] [Related]
17. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
[TBL] [Abstract][Full Text] [Related]
18. EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
Noh CK; Wang HJ; Kim CM; Kim J; Yoon SY; Lee GH; Cho HJ; Yang MJ; Kim SS; Hwang JC; Cho SW; Roh J; Kim YB; Kim SJ; Kim BW; Cheong JY
Anticancer Res; 2018 Jul; 38(7):4101-4109. PubMed ID: 29970536
[TBL] [Abstract][Full Text] [Related]
19. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.
Zhao RC; Zhou J; Chen KF; Gong J; Liu J; He JY; Guan P; Li B; Qin Y
Neoplasma; 2016; 63(2):288-98. PubMed ID: 26674131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
